Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Zinc finger and BTB domain-containing protein 6 (ZBTB6) is a member of the ZBTB family, characterized by a C-terminal zinc finger domain enabling sequence-specific DNA binding and an N-terminal BTB (POZ) domain mediating protein–protein interactions[1][3]. It mainly acts as a transcriptional repressor, recruiting corepressors (such as N-CoR, SMRT, and HDACs) to gene promoters via its BTB domain. ZBTB6 is implicated in regulating negative transcription by RNA polymerase II, cytokine production, immune process regulation, cell cycle progression, apoptosis, and cell proliferation. It is highly expressed in several cancers, especially breast cancer, where it promotes tumor progression through repression of ARHGAP6 and activation of the STAT3 signaling pathway[1]. Its overexpression correlates with higher tumor grade and worse prognosis. ZBTB6 is considered a potential prognostic indicator and possible chemotherapeutic target in cancer[1][3][4].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Zinc finger and BTB domain-containing protein 6 (ZBTB6).